LAS VEGAS--(BUSINESS WIRE)--GeoVax Labs, Inc. (OTCBB:GOVX), an Atlanta-based biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, together with VGX International (VGXI), announced today at the International Society of DNA Vaccines Conference, held in Las Vegas, Nevada, the execution of a Master Product Sale Agreement between VGXI and GeoVax, whereby VGXI will manufacture plasmid, namely the JS2-DNA vaccine, for use in GeoVax’s future preventative and therapeutic clinical human trials.
